I met Dr Akira Yamamoto for the first time when I was a student at Shiga University of Medical Science, Graduate School. I was researching the action of insulin on LDL cholesterol in familial hypercholesterolemia (FH) and presenting at the annual meeting of the Japanese Atherosclerosis Society. Dr Akira Yamamoto helped me when I was struggling with difficult questions. He was wearing a tremendous aura from being at the leading edge in the world at that time, after the first‐in‐human study of a statin and the development of LDL apheresis. After that, I became a postdoctoral fellow of the Department of Etiology and Pathophysiology at the National Cardiovascular Center Research Institute, and started clinical and basic research on FH. Dr Yamamoto gave us huge freedom in selecting research themes and how to proceed. For example, there was no check or rehearsal before any presentations at conferences. One time, after I gave a presentation at the meeting of the Japanese Atherosclerosis Society, Dr Yamamoto came to me and said, "You are working on an interesting theme!" I do not know any other boss who gives such huge freedom to the researchers.

He has contributed to the establishment of the Japanese Society for Apheresis, the International Society for Apheresis, and the Asian‐Pacific Society of Atherosclerosis and Vascular Disease, and he was committed to the development of academic and medical sciences not only in Japan but also throughout the world. His first‐in‐human study of a statin was the starting point, and statins have been shown to be effective in preventing atherosclerotic cardiovascular disease and have played a major role in public health worldwide. In addition, patients with FH, who have atherosclerotic cardiovascular disease at a young age, received tremendous benefit from statins by improving their prognosis dramatically. Dr Yamamoto's development of LDL apheresis enabled selective removal of LDL for the treatment of homozygous FH. The therapeutic indication of LDL apheresis is expanding to include such conditions as severe heterozygous FH, arteriosclerosis obliterans, and focal glomerulosclerosis. The number of patients receiving benefits from these techniques has been also increasing dramatically.

Having learnt a lot under Dr Akira Yamamoto, I will proudly continue to work on FH medical care. Dr Akira Yamamoto, thank you very much.
